Compound library / Fat Loss / GLP-1

Semaglutide

GLP-1 receptor agonist, FDA-approved (Ozempic/Wegovy) for type 2 diabetes and chronic weight management.

CategoryFat Loss / GLP-1
Regulatory standingApproved medicine
Typical routeSubcutaneous
Half-life~1 week
Common dose range0.25-2.4 mg/week, titrated
Typical cycle lengthOngoing under medical supervision

BioHack Track models Semaglutide at a half-life of 168 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

Approved medicine

An FDA-approved product containing this compound exists, and its label is linked under Primary sources below. That label is the authority on dosing; the range on this page describes what people commonly track, including off-label use, and does not replace it.

Reconstitution

Typically supplied pre-filled; compounded versions require reconstitution per pharmacy instructions.

Storage

Refrigerate; some pens stable at room temp short-term per label.

Cautions

Prescription medication — requires medical supervision. GI side effects common; contraindicated with personal/family history of medullary thyroid carcinoma.

Track Semaglutide in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Fat Loss / GLP-1

Look up the research

These open a search of each database for Semaglutide — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support